nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A4—Thiotepa—urinary bladder cancer	0.0563	0.182	CbGbCtD
Ondansetron—CYP2E1—Etoposide—urinary bladder cancer	0.0503	0.162	CbGbCtD
Ondansetron—CYP3A5—Etoposide—urinary bladder cancer	0.0391	0.126	CbGbCtD
Ondansetron—CYP1A2—Fluorouracil—urinary bladder cancer	0.0349	0.113	CbGbCtD
Ondansetron—CYP2C9—Fluorouracil—urinary bladder cancer	0.0314	0.101	CbGbCtD
Ondansetron—CYP1A2—Etoposide—urinary bladder cancer	0.0291	0.094	CbGbCtD
Ondansetron—CYP2C9—Cisplatin—urinary bladder cancer	0.0267	0.0862	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—urinary bladder cancer	0.0164	0.0528	CbGbCtD
Ondansetron—CYP3A4—Etoposide—urinary bladder cancer	0.0153	0.0492	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—urinary bladder cancer	0.0104	0.0336	CbGbCtD
Ondansetron—SLC47A2—renal system—urinary bladder cancer	0.00928	0.0872	CbGeAlD
Ondansetron—CYP1A2—urine—urinary bladder cancer	0.00697	0.0655	CbGeAlD
Ondansetron—SLC47A2—vagina—urinary bladder cancer	0.00672	0.0631	CbGeAlD
Ondansetron—CYP2C9—urine—urinary bladder cancer	0.00662	0.0622	CbGeAlD
Ondansetron—CYP2E1—urine—urinary bladder cancer	0.00627	0.0589	CbGeAlD
Ondansetron—CYP3A4—urine—urinary bladder cancer	0.00505	0.0474	CbGeAlD
Ondansetron—CYP2D6—urine—urinary bladder cancer	0.00497	0.0466	CbGeAlD
Ondansetron—SLC47A1—prostate gland—urinary bladder cancer	0.00477	0.0448	CbGeAlD
Ondansetron—SLC47A1—seminal vesicle—urinary bladder cancer	0.00403	0.0379	CbGeAlD
Ondansetron—SLC47A1—renal system—urinary bladder cancer	0.00325	0.0305	CbGeAlD
Ondansetron—SLC47A1—urethra—urinary bladder cancer	0.00319	0.03	CbGeAlD
Ondansetron—KCNH2—prostate gland—urinary bladder cancer	0.00292	0.0275	CbGeAlD
Ondansetron—SLC47A1—female reproductive system—urinary bladder cancer	0.0026	0.0244	CbGeAlD
Ondansetron—KCNH2—seminal vesicle—urinary bladder cancer	0.00247	0.0232	CbGeAlD
Ondansetron—CYP3A5—prostate gland—urinary bladder cancer	0.00241	0.0227	CbGeAlD
Ondansetron—SLC47A1—vagina—urinary bladder cancer	0.00235	0.0221	CbGeAlD
Ondansetron—CYP2E1—prostate gland—urinary bladder cancer	0.00225	0.0211	CbGeAlD
Ondansetron—HTR1A—renal system—urinary bladder cancer	0.00224	0.021	CbGeAlD
Ondansetron—HTR1B—female reproductive system—urinary bladder cancer	0.00222	0.0209	CbGeAlD
Ondansetron—KCNH2—renal system—urinary bladder cancer	0.00199	0.0187	CbGeAlD
Ondansetron—KCNH2—urethra—urinary bladder cancer	0.00196	0.0184	CbGeAlD
Ondansetron—CYP2E1—seminal vesicle—urinary bladder cancer	0.0019	0.0179	CbGeAlD
Ondansetron—CYP1A2—renal system—urinary bladder cancer	0.00171	0.016	CbGeAlD
Ondansetron—CYP3A5—renal system—urinary bladder cancer	0.00165	0.0155	CbGeAlD
Ondansetron—KCNH2—female reproductive system—urinary bladder cancer	0.0016	0.015	CbGeAlD
Ondansetron—CYP2E1—renal system—urinary bladder cancer	0.00153	0.0144	CbGeAlD
Ondansetron—SLC47A1—lymph node—urinary bladder cancer	0.00152	0.0143	CbGeAlD
Ondansetron—CYP2E1—urethra—urinary bladder cancer	0.00151	0.0142	CbGeAlD
Ondansetron—KCNH2—vagina—urinary bladder cancer	0.00144	0.0136	CbGeAlD
Ondansetron—CYP2C9—female reproductive system—urinary bladder cancer	0.0013	0.0122	CbGeAlD
Ondansetron—CYP3A4—renal system—urinary bladder cancer	0.00123	0.0116	CbGeAlD
Ondansetron—CYP2E1—female reproductive system—urinary bladder cancer	0.00123	0.0115	CbGeAlD
Ondansetron—CYP2D6—renal system—urinary bladder cancer	0.00122	0.0114	CbGeAlD
Ondansetron—CYP3A5—vagina—urinary bladder cancer	0.00119	0.0112	CbGeAlD
Ondansetron—CYP3A4—female reproductive system—urinary bladder cancer	0.000989	0.00929	CbGeAlD
Ondansetron—CYP2D6—female reproductive system—urinary bladder cancer	0.000973	0.00914	CbGeAlD
Ondansetron—KCNH2—lymph node—urinary bladder cancer	0.000934	0.00877	CbGeAlD
Ondansetron—Somnolence—Fluorouracil—urinary bladder cancer	0.000557	0.00135	CcSEcCtD
Ondansetron—Hypotension—Cisplatin—urinary bladder cancer	0.000555	0.00135	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00055	0.00133	CcSEcCtD
Ondansetron—Fatigue—Gemcitabine—urinary bladder cancer	0.000549	0.00133	CcSEcCtD
Ondansetron—Pain—Gemcitabine—urinary bladder cancer	0.000545	0.00132	CcSEcCtD
Ondansetron—Constipation—Gemcitabine—urinary bladder cancer	0.000545	0.00132	CcSEcCtD
Ondansetron—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000544	0.00132	CcSEcCtD
Ondansetron—Asthenia—Thiotepa—urinary bladder cancer	0.000543	0.00132	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000541	0.00131	CcSEcCtD
Ondansetron—Asthma—Epirubicin—urinary bladder cancer	0.000536	0.0013	CcSEcCtD
Ondansetron—Dysuria—Methotrexate—urinary bladder cancer	0.000536	0.0013	CcSEcCtD
Ondansetron—Pruritus—Thiotepa—urinary bladder cancer	0.000536	0.0013	CcSEcCtD
Ondansetron—Pain—Fluorouracil—urinary bladder cancer	0.000536	0.0013	CcSEcCtD
Ondansetron—Paraesthesia—Cisplatin—urinary bladder cancer	0.000533	0.00129	CcSEcCtD
Ondansetron—Tachycardia—Etoposide—urinary bladder cancer	0.000531	0.00129	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00053	0.00129	CcSEcCtD
Ondansetron—Dyspnoea—Cisplatin—urinary bladder cancer	0.000529	0.00128	CcSEcCtD
Ondansetron—Skin disorder—Etoposide—urinary bladder cancer	0.000528	0.00128	CcSEcCtD
Ondansetron—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000525	0.00127	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000522	0.00127	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—urinary bladder cancer	0.000522	0.00127	CcSEcCtD
Ondansetron—Diarrhoea—Thiotepa—urinary bladder cancer	0.000518	0.00126	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000517	0.00125	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000517	0.00125	CcSEcCtD
Ondansetron—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000516	0.00125	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000513	0.00124	CcSEcCtD
Ondansetron—Drowsiness—Methotrexate—urinary bladder cancer	0.000511	0.00124	CcSEcCtD
Ondansetron—Hypotension—Etoposide—urinary bladder cancer	0.000508	0.00123	CcSEcCtD
Ondansetron—Pain—Cisplatin—urinary bladder cancer	0.000508	0.00123	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000507	0.00123	CcSEcCtD
Ondansetron—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000504	0.00122	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—urinary bladder cancer	0.000501	0.00122	CcSEcCtD
Ondansetron—Dizziness—Thiotepa—urinary bladder cancer	0.000501	0.00122	CcSEcCtD
Ondansetron—Urticaria—Fluorouracil—urinary bladder cancer	0.000498	0.00121	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—urinary bladder cancer	0.000496	0.0012	CcSEcCtD
Ondansetron—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000495	0.0012	CcSEcCtD
Ondansetron—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000489	0.00119	CcSEcCtD
Ondansetron—Paraesthesia—Etoposide—urinary bladder cancer	0.000489	0.00119	CcSEcCtD
Ondansetron—Dyspnoea—Etoposide—urinary bladder cancer	0.000485	0.00118	CcSEcCtD
Ondansetron—Somnolence—Etoposide—urinary bladder cancer	0.000484	0.00117	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000483	0.00117	CcSEcCtD
Ondansetron—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000483	0.00117	CcSEcCtD
Ondansetron—Vomiting—Thiotepa—urinary bladder cancer	0.000482	0.00117	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—urinary bladder cancer	0.000478	0.00116	CcSEcCtD
Ondansetron—Rash—Thiotepa—urinary bladder cancer	0.000478	0.00116	CcSEcCtD
Ondansetron—Dermatitis—Thiotepa—urinary bladder cancer	0.000477	0.00116	CcSEcCtD
Ondansetron—Headache—Thiotepa—urinary bladder cancer	0.000474	0.00115	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000474	0.00115	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00047	0.00114	CcSEcCtD
Ondansetron—Body temperature increased—Cisplatin—urinary bladder cancer	0.000469	0.00114	CcSEcCtD
Ondansetron—Fatigue—Etoposide—urinary bladder cancer	0.000469	0.00114	CcSEcCtD
Ondansetron—Constipation—Etoposide—urinary bladder cancer	0.000465	0.00113	CcSEcCtD
Ondansetron—Pain—Etoposide—urinary bladder cancer	0.000465	0.00113	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000465	0.00113	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—urinary bladder cancer	0.000464	0.00113	CcSEcCtD
Ondansetron—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000462	0.00112	CcSEcCtD
Ondansetron—Haemoglobin—Methotrexate—urinary bladder cancer	0.000461	0.00112	CcSEcCtD
Ondansetron—Haemorrhage—Methotrexate—urinary bladder cancer	0.000459	0.00111	CcSEcCtD
Ondansetron—Asthenia—Gemcitabine—urinary bladder cancer	0.000457	0.00111	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000452	0.0011	CcSEcCtD
Ondansetron—Pruritus—Gemcitabine—urinary bladder cancer	0.000451	0.00109	CcSEcCtD
Ondansetron—Feeling abnormal—Etoposide—urinary bladder cancer	0.000448	0.00109	CcSEcCtD
Ondansetron—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000445	0.00108	CcSEcCtD
Ondansetron—Pruritus—Fluorouracil—urinary bladder cancer	0.000443	0.00108	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—urinary bladder cancer	0.000442	0.00107	CcSEcCtD
Ondansetron—Visual impairment—Methotrexate—urinary bladder cancer	0.000442	0.00107	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000439	0.00106	CcSEcCtD
Ondansetron—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000438	0.00106	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—urinary bladder cancer	0.000437	0.00106	CcSEcCtD
Ondansetron—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000436	0.00106	CcSEcCtD
Ondansetron—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000434	0.00105	CcSEcCtD
Ondansetron—Urticaria—Etoposide—urinary bladder cancer	0.000432	0.00105	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—urinary bladder cancer	0.000431	0.00105	CcSEcCtD
Ondansetron—Abdominal pain—Etoposide—urinary bladder cancer	0.00043	0.00104	CcSEcCtD
Ondansetron—Body temperature increased—Etoposide—urinary bladder cancer	0.00043	0.00104	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00043	0.00104	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—urinary bladder cancer	0.000429	0.00104	CcSEcCtD
Ondansetron—Eye disorder—Methotrexate—urinary bladder cancer	0.000429	0.00104	CcSEcCtD
Ondansetron—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000429	0.00104	CcSEcCtD
Ondansetron—Asthenia—Cisplatin—urinary bladder cancer	0.000426	0.00103	CcSEcCtD
Ondansetron—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000426	0.00103	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000418	0.00102	CcSEcCtD
Ondansetron—Angiopathy—Methotrexate—urinary bladder cancer	0.000416	0.00101	CcSEcCtD
Ondansetron—Immune system disorder—Methotrexate—urinary bladder cancer	0.000414	0.00101	CcSEcCtD
Ondansetron—Dizziness—Fluorouracil—urinary bladder cancer	0.000414	0.00101	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—urinary bladder cancer	0.000414	0.001	CcSEcCtD
Ondansetron—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000413	0.001	CcSEcCtD
Ondansetron—Chills—Methotrexate—urinary bladder cancer	0.000412	0.000999	CcSEcCtD
Ondansetron—Diarrhoea—Cisplatin—urinary bladder cancer	0.000406	0.000986	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000406	0.000985	CcSEcCtD
Ondansetron—Vomiting—Gemcitabine—urinary bladder cancer	0.000405	0.000983	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—urinary bladder cancer	0.000404	0.000981	CcSEcCtD
Ondansetron—Rash—Gemcitabine—urinary bladder cancer	0.000402	0.000975	CcSEcCtD
Ondansetron—Dermatitis—Gemcitabine—urinary bladder cancer	0.000401	0.000974	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—urinary bladder cancer	0.000401	0.000973	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—urinary bladder cancer	0.000401	0.000973	CcSEcCtD
Ondansetron—Erythema—Methotrexate—urinary bladder cancer	0.000399	0.000969	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000399	0.000969	CcSEcCtD
Ondansetron—Headache—Gemcitabine—urinary bladder cancer	0.000399	0.000968	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000398	0.000967	CcSEcCtD
Ondansetron—Flushing—Epirubicin—urinary bladder cancer	0.000398	0.000967	CcSEcCtD
Ondansetron—Vomiting—Fluorouracil—urinary bladder cancer	0.000398	0.000966	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000397	0.000964	CcSEcCtD
Ondansetron—Rash—Fluorouracil—urinary bladder cancer	0.000395	0.000958	CcSEcCtD
Ondansetron—Dermatitis—Fluorouracil—urinary bladder cancer	0.000395	0.000958	CcSEcCtD
Ondansetron—Headache—Fluorouracil—urinary bladder cancer	0.000392	0.000952	CcSEcCtD
Ondansetron—Asthenia—Etoposide—urinary bladder cancer	0.00039	0.000947	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—urinary bladder cancer	0.000389	0.000945	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—urinary bladder cancer	0.000388	0.000941	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000387	0.000939	CcSEcCtD
Ondansetron—Chills—Epirubicin—urinary bladder cancer	0.000385	0.000935	CcSEcCtD
Ondansetron—Pruritus—Etoposide—urinary bladder cancer	0.000385	0.000934	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—urinary bladder cancer	0.000383	0.00093	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—urinary bladder cancer	0.000383	0.000929	CcSEcCtD
Ondansetron—Vomiting—Cisplatin—urinary bladder cancer	0.000378	0.000916	CcSEcCtD
Ondansetron—Vision blurred—Methotrexate—urinary bladder cancer	0.000376	0.000913	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000376	0.000911	CcSEcCtD
Ondansetron—Rash—Cisplatin—urinary bladder cancer	0.000374	0.000909	CcSEcCtD
Ondansetron—Dermatitis—Cisplatin—urinary bladder cancer	0.000374	0.000908	CcSEcCtD
Ondansetron—Erythema—Epirubicin—urinary bladder cancer	0.000374	0.000907	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—urinary bladder cancer	0.000372	0.000903	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—urinary bladder cancer	0.000371	0.000901	CcSEcCtD
Ondansetron—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00037	0.000899	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—urinary bladder cancer	0.000369	0.000894	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000369	0.000894	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—urinary bladder cancer	0.000368	0.000893	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—urinary bladder cancer	0.00036	0.000874	CcSEcCtD
Ondansetron—Malaise—Methotrexate—urinary bladder cancer	0.00036	0.000874	CcSEcCtD
Ondansetron—Dizziness—Etoposide—urinary bladder cancer	0.00036	0.000873	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000359	0.00087	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000358	0.000869	CcSEcCtD
Ondansetron—Chills—Doxorubicin—urinary bladder cancer	0.000356	0.000865	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000355	0.000861	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—urinary bladder cancer	0.000352	0.000855	CcSEcCtD
Ondansetron—Cough—Methotrexate—urinary bladder cancer	0.000348	0.000845	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000347	0.000841	CcSEcCtD
Ondansetron—Convulsion—Methotrexate—urinary bladder cancer	0.000346	0.000839	CcSEcCtD
Ondansetron—Vomiting—Etoposide—urinary bladder cancer	0.000346	0.000839	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—urinary bladder cancer	0.000346	0.000839	CcSEcCtD
Ondansetron—Agitation—Epirubicin—urinary bladder cancer	0.000343	0.000833	CcSEcCtD
Ondansetron—Rash—Etoposide—urinary bladder cancer	0.000343	0.000832	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—urinary bladder cancer	0.000343	0.000832	CcSEcCtD
Ondansetron—Headache—Etoposide—urinary bladder cancer	0.000341	0.000827	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—urinary bladder cancer	0.000341	0.000827	CcSEcCtD
Ondansetron—Chest pain—Methotrexate—urinary bladder cancer	0.00034	0.000825	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000338	0.000819	CcSEcCtD
Ondansetron—Malaise—Epirubicin—urinary bladder cancer	0.000337	0.000818	CcSEcCtD
Ondansetron—Discomfort—Methotrexate—urinary bladder cancer	0.000336	0.000815	CcSEcCtD
Ondansetron—Syncope—Epirubicin—urinary bladder cancer	0.000335	0.000813	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—urinary bladder cancer	0.00033	0.000801	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000328	0.000797	CcSEcCtD
Ondansetron—Cough—Epirubicin—urinary bladder cancer	0.000326	0.000791	CcSEcCtD
Ondansetron—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000326	0.000791	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—urinary bladder cancer	0.000326	0.000791	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—urinary bladder cancer	0.000324	0.000786	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000321	0.000778	CcSEcCtD
Ondansetron—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00032	0.000775	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—urinary bladder cancer	0.000318	0.000772	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—urinary bladder cancer	0.000318	0.000771	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—urinary bladder cancer	0.000317	0.000769	CcSEcCtD
Ondansetron—Skin disorder—Methotrexate—urinary bladder cancer	0.000317	0.000768	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000316	0.000767	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—urinary bladder cancer	0.000314	0.000763	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—urinary bladder cancer	0.000312	0.000757	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—urinary bladder cancer	0.000311	0.000755	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—urinary bladder cancer	0.00031	0.000752	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—urinary bladder cancer	0.000306	0.000741	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000305	0.00074	CcSEcCtD
Ondansetron—Hypotension—Methotrexate—urinary bladder cancer	0.000304	0.000739	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000304	0.000737	CcSEcCtD
Ondansetron—Cough—Doxorubicin—urinary bladder cancer	0.000302	0.000732	CcSEcCtD
Ondansetron—Shock—Epirubicin—urinary bladder cancer	0.0003	0.000728	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—urinary bladder cancer	0.0003	0.000727	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000299	0.000726	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—urinary bladder cancer	0.000298	0.000722	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—urinary bladder cancer	0.000296	0.000719	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—urinary bladder cancer	0.000294	0.000714	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—urinary bladder cancer	0.000293	0.000712	CcSEcCtD
Ondansetron—Paraesthesia—Methotrexate—urinary bladder cancer	0.000293	0.00071	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000292	0.000709	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—urinary bladder cancer	0.000291	0.000706	CcSEcCtD
Ondansetron—Dyspnoea—Methotrexate—urinary bladder cancer	0.000291	0.000705	CcSEcCtD
Ondansetron—Somnolence—Methotrexate—urinary bladder cancer	0.00029	0.000703	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—urinary bladder cancer	0.000288	0.000699	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—urinary bladder cancer	0.000285	0.000691	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000282	0.000685	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000281	0.000683	CcSEcCtD
Ondansetron—Fatigue—Methotrexate—urinary bladder cancer	0.000281	0.000682	CcSEcCtD
Ondansetron—Pain—Methotrexate—urinary bladder cancer	0.000279	0.000676	CcSEcCtD
Ondansetron—Shock—Doxorubicin—urinary bladder cancer	0.000278	0.000674	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000277	0.000671	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—urinary bladder cancer	0.000275	0.000668	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—urinary bladder cancer	0.000274	0.000665	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—urinary bladder cancer	0.000274	0.000664	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—urinary bladder cancer	0.000272	0.00066	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—urinary bladder cancer	0.000271	0.000658	CcSEcCtD
Ondansetron—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000269	0.000652	CcSEcCtD
Ondansetron—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000266	0.000647	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—urinary bladder cancer	0.000264	0.00064	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000263	0.000639	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—urinary bladder cancer	0.000263	0.000638	CcSEcCtD
Ondansetron—Pain—Epirubicin—urinary bladder cancer	0.000261	0.000633	CcSEcCtD
Ondansetron—Constipation—Epirubicin—urinary bladder cancer	0.000261	0.000633	CcSEcCtD
Ondansetron—Urticaria—Methotrexate—urinary bladder cancer	0.000259	0.000628	CcSEcCtD
Ondansetron—Abdominal pain—Methotrexate—urinary bladder cancer	0.000258	0.000625	CcSEcCtD
Ondansetron—Body temperature increased—Methotrexate—urinary bladder cancer	0.000258	0.000625	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000253	0.000615	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000252	0.00061	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000251	0.00061	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—urinary bladder cancer	0.000251	0.000609	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000249	0.000605	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000244	0.000591	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—urinary bladder cancer	0.000243	0.00059	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—urinary bladder cancer	0.000242	0.000588	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—urinary bladder cancer	0.000241	0.000586	CcSEcCtD
Ondansetron—Pain—Doxorubicin—urinary bladder cancer	0.000241	0.000586	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—urinary bladder cancer	0.000241	0.000585	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—urinary bladder cancer	0.000241	0.000585	CcSEcCtD
Ondansetron—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00024	0.000583	CcSEcCtD
Ondansetron—Asthenia—Methotrexate—urinary bladder cancer	0.000234	0.000567	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000233	0.000564	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000231	0.00056	CcSEcCtD
Ondansetron—Pruritus—Methotrexate—urinary bladder cancer	0.000231	0.000559	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000225	0.000545	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—urinary bladder cancer	0.000224	0.000544	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000223	0.000541	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000223	0.000541	CcSEcCtD
Ondansetron—Diarrhoea—Methotrexate—urinary bladder cancer	0.000223	0.000541	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—urinary bladder cancer	0.000219	0.000531	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—urinary bladder cancer	0.000216	0.000524	CcSEcCtD
Ondansetron—Dizziness—Methotrexate—urinary bladder cancer	0.000215	0.000523	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—urinary bladder cancer	0.000209	0.000506	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000208	0.000504	CcSEcCtD
Ondansetron—Vomiting—Methotrexate—urinary bladder cancer	0.000207	0.000503	CcSEcCtD
Ondansetron—Rash—Methotrexate—urinary bladder cancer	0.000205	0.000499	CcSEcCtD
Ondansetron—Dermatitis—Methotrexate—urinary bladder cancer	0.000205	0.000498	CcSEcCtD
Ondansetron—Headache—Methotrexate—urinary bladder cancer	0.000204	0.000495	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—urinary bladder cancer	0.000202	0.000491	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—urinary bladder cancer	0.000202	0.000489	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—urinary bladder cancer	0.0002	0.000484	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—urinary bladder cancer	0.000194	0.00047	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000193	0.000468	CcSEcCtD
Ondansetron—Rash—Epirubicin—urinary bladder cancer	0.000192	0.000467	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—urinary bladder cancer	0.000192	0.000466	CcSEcCtD
Ondansetron—Headache—Epirubicin—urinary bladder cancer	0.000191	0.000464	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—urinary bladder cancer	0.000187	0.000453	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—urinary bladder cancer	0.000179	0.000435	CcSEcCtD
Ondansetron—Rash—Doxorubicin—urinary bladder cancer	0.000178	0.000432	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—urinary bladder cancer	0.000178	0.000431	CcSEcCtD
Ondansetron—Headache—Doxorubicin—urinary bladder cancer	0.000177	0.000429	CcSEcCtD
Ondansetron—HTR4—Signaling Pathways—MMP9—urinary bladder cancer	4.73e-05	0.000276	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CDKN1A—urinary bladder cancer	4.71e-05	0.000275	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTEN—urinary bladder cancer	4.7e-05	0.000274	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RBX1—urinary bladder cancer	4.67e-05	0.000272	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	4.64e-05	0.00027	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—RRM2—urinary bladder cancer	4.59e-05	0.000268	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—RRM2—urinary bladder cancer	4.58e-05	0.000267	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	4.54e-05	0.000265	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.51e-05	0.000263	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.51e-05	0.000263	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EP300—urinary bladder cancer	4.49e-05	0.000261	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—S100B—urinary bladder cancer	4.44e-05	0.000259	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	4.42e-05	0.000258	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TSC1—urinary bladder cancer	4.39e-05	0.000256	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SRC—urinary bladder cancer	4.36e-05	0.000254	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ENO2—urinary bladder cancer	4.25e-05	0.000248	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	4.25e-05	0.000248	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.24e-05	0.000247	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.24e-05	0.000247	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—RHOA—urinary bladder cancer	4.21e-05	0.000246	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—JAG1—urinary bladder cancer	4.18e-05	0.000244	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.17e-05	0.000243	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.15e-05	0.000242	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.14e-05	0.000241	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	4.13e-05	0.00024	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.12e-05	0.00024	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.12e-05	0.00024	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	4.09e-05	0.000239	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.07e-05	0.000237	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NCOR1—urinary bladder cancer	4e-05	0.000233	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.97e-05	0.000232	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	3.95e-05	0.00023	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	3.92e-05	0.000229	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MYC—urinary bladder cancer	3.91e-05	0.000228	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—IL2—urinary bladder cancer	3.89e-05	0.000227	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EGFR—urinary bladder cancer	3.82e-05	0.000223	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.78e-05	0.00022	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.74e-05	0.000218	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	3.72e-05	0.000217	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.71e-05	0.000216	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	3.7e-05	0.000216	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TYMS—urinary bladder cancer	3.67e-05	0.000214	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	3.63e-05	0.000211	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	3.63e-05	0.000211	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KRAS—urinary bladder cancer	3.61e-05	0.00021	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.59e-05	0.00021	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.55e-05	0.000207	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMP—urinary bladder cancer	3.54e-05	0.000206	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL2—urinary bladder cancer	3.54e-05	0.000206	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	3.53e-05	0.000206	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	3.53e-05	0.000206	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TERT—urinary bladder cancer	3.52e-05	0.000205	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.5e-05	0.000204	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.47e-05	0.000202	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	3.44e-05	0.0002	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NQO1—urinary bladder cancer	3.43e-05	0.0002	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.42e-05	0.000199	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.41e-05	0.000199	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.41e-05	0.000199	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.4e-05	0.000198	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—S100B—urinary bladder cancer	3.39e-05	0.000197	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.26e-05	0.00019	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.26e-05	0.00019	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	3.23e-05	0.000188	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.23e-05	0.000188	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—RHOA—urinary bladder cancer	3.21e-05	0.000187	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—urinary bladder cancer	3.21e-05	0.000187	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	3.21e-05	0.000187	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.2e-05	0.000186	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	3.14e-05	0.000183	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	3.12e-05	0.000182	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	3.11e-05	0.000181	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.1e-05	0.000181	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—urinary bladder cancer	3.07e-05	0.000179	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	3.04e-05	0.000177	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.02e-05	0.000176	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.02e-05	0.000176	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.99e-05	0.000174	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.99e-05	0.000174	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.97e-05	0.000173	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	2.97e-05	0.000173	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.93e-05	0.000171	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.9e-05	0.000169	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	2.86e-05	0.000167	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.86e-05	0.000167	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.85e-05	0.000166	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	2.85e-05	0.000166	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.82e-05	0.000164	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	2.77e-05	0.000161	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.76e-05	0.000161	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	2.75e-05	0.00016	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.73e-05	0.000159	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	2.72e-05	0.000158	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	2.7e-05	0.000158	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	2.69e-05	0.000157	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	2.68e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TYMS—urinary bladder cancer	2.66e-05	0.000155	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.65e-05	0.000155	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	2.63e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	2.63e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.62e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.62e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.6e-05	0.000152	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.56e-05	0.000149	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.56e-05	0.000149	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	2.55e-05	0.000149	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.54e-05	0.000148	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GPX1—urinary bladder cancer	2.52e-05	0.000147	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.51e-05	0.000146	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.5e-05	0.000146	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	2.49e-05	0.000145	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.48e-05	0.000145	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	2.47e-05	0.000144	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.47e-05	0.000144	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.47e-05	0.000144	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	2.46e-05	0.000144	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.44e-05	0.000142	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.43e-05	0.000142	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	2.43e-05	0.000142	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.41e-05	0.000141	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	2.4e-05	0.00014	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	2.39e-05	0.000139	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	2.39e-05	0.000139	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.34e-05	0.000136	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.32e-05	0.000135	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.32e-05	0.000135	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.3e-05	0.000134	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	2.25e-05	0.000131	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	2.2e-05	0.000128	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.19e-05	0.000127	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	2.17e-05	0.000127	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.13e-05	0.000124	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.1e-05	0.000122	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	2.09e-05	0.000122	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	2.07e-05	0.000121	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.06e-05	0.00012	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	2.06e-05	0.00012	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	2.05e-05	0.000119	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.04e-05	0.000119	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	2.04e-05	0.000119	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	2.03e-05	0.000119	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.03e-05	0.000118	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.01e-05	0.000117	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2e-05	0.000117	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	1.98e-05	0.000115	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.97e-05	0.000115	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.97e-05	0.000115	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.97e-05	0.000115	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	1.96e-05	0.000115	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.95e-05	0.000113	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.95e-05	0.000113	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.93e-05	0.000112	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.92e-05	0.000112	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.91e-05	0.000112	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.9e-05	0.000111	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.89e-05	0.00011	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.88e-05	0.00011	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.88e-05	0.00011	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	1.87e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.87e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.85e-05	0.000108	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.85e-05	0.000108	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	1.84e-05	0.000107	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	1.82e-05	0.000106	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1.81e-05	0.000105	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.81e-05	0.000105	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.8e-05	0.000105	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.79e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.78e-05	0.000104	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.77e-05	0.000103	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.76e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000102	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.74e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.74e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.74e-05	0.000101	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.74e-05	0.000101	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.73e-05	0.000101	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.72e-05	0.0001	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.7e-05	9.91e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.66e-05	9.7e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.66e-05	9.69e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.65e-05	9.64e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	1.65e-05	9.64e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.65e-05	9.61e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.63e-05	9.52e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	1.63e-05	9.52e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	1.61e-05	9.37e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.6e-05	9.31e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	1.6e-05	9.31e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.59e-05	9.27e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.59e-05	9.27e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	9.21e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	9.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.55e-05	9.04e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.51e-05	8.82e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.51e-05	8.79e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.51e-05	8.78e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.5e-05	8.74e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-05	8.72e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.49e-05	8.66e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.48e-05	8.63e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.48e-05	8.62e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	1.44e-05	8.4e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.43e-05	8.32e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-05	8.22e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.4e-05	8.14e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.39e-05	8.09e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.34e-05	7.82e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.34e-05	7.79e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.33e-05	7.76e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.33e-05	7.73e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.32e-05	7.72e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.29e-05	7.53e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.29e-05	7.51e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	7.48e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-05	7.48e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.27e-05	7.42e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.24e-05	7.25e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.23e-05	7.19e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.23e-05	7.18e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.23e-05	7.17e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.22e-05	7.11e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.22e-05	7.11e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-05	7.09e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	1.18e-05	6.9e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.17e-05	6.81e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	6.7e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.15e-05	6.68e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.13e-05	6.6e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	1.13e-05	6.6e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.09e-05	6.34e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.08e-05	6.28e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.05e-05	6.13e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	6.07e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.02e-05	5.95e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	9.77e-06	5.69e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.17e-06	5.34e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.09e-06	5.3e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	8.91e-06	5.19e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—EP300—urinary bladder cancer	8.74e-06	5.1e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.74e-06	5.09e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—EP300—urinary bladder cancer	8.67e-06	5.05e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.39e-06	4.89e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—urinary bladder cancer	7.77e-06	4.53e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.41e-06	4.32e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.87e-06	4.01e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.99e-06	3.49e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.72e-06	3.33e-05	CbGpPWpGaD
